Probing the Interface of HIV and Inflammaging

Purpose of Review Systemic inflammation increases as a consequence of aging (inflammaging) and contributes to age-related morbidities. Inflammation in people living with HIV is elevated compared with the general population even after prolonged suppression of viremia with anti-retroviral therapy. Mechanisms that contribute to inflammation during aging and in treated HIV disease are potentially interactive, leading to an exaggerated inflammatory phenotype in people with HIV. Recent Findings Recent studies highlight roles for anti-retroviral therapy, co-infections, immune system alterations, and microbiome perturbations as important contributors to HIV-associated inflammation. These factors likely contribute to increased risk of age-related morbidities in people living with HIV. Understanding mechanisms that exaggerate the inflammaging process in people with HIV may lead to improved intervention strategies, ultimately, extending both lifespan and healthspan.

Automated summary

Recent studies have shown that factors such as anti-retroviral therapy, co-infections, immune system alterations, and microbiome perturbations contribute to HIV-associated inflammation, potentially increasing the risk of age-related morbidities in people living with HIV. Understanding the mechanisms that exacerbate inflammaging in people with HIV may lead to improved intervention strategies, ultimately extending both lifespan and healthspan.